Individualized starting dose (ISD) of maintenance niraparib improves progression-free survival (PFS) vs placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), results of the NORA trial have shown.
Pembrolizumab monotherapy improves overall
survival (OS) and cancer control compared with platinum-based chemotherapy in
patients with untreated locally advanced or metastatic programmed death-ligand
1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11
or KEAP1 mutation status, according to results of the phase III